Migraine



More than a billion people suffer from migraine attacks each year

It represents
the 6th most
common cause
of disability on
the planet¹

Migraine is a primary headache disorder; migraine with or without aura being the two major types²





The societal cost of migraine is huge, costing €27 billion a year in Europe alone³



Acute therapies

for migraine include NSAIDs, analgesics and triptans, where early intervention can shorten the time it takes to reach a painfree response⁴



Anti-CGRP monoclonal antibodies have the potential to **individualise preventive treatment.**⁵



Migraine without aura:2

Unilateral, pulsating headache attacks lasting 4-72 hours, associated with nausea and/or photophobia and phonophobia



Migraine with aura:²

Unilateral, shortlasting headache attacks with reversible visual, sensory or central nervous system symptoms



CGRP, calcitonin gene-related peptide; NSAID, non-steroidal anti-inflammatory drug

1. Goadsby PJ et al. Physiol Rev. 2017;97:553–622. 2. ICHD-3. Cephalalgia. 2018;38(1):1–211. 3. European Brain Council (EBC). Available at: http://ebc-brussels.org/wp-content/uploads/2015/07/Migraine-fact-sheet-Sept-2011.pdf. 4. May A & Schulte LH. Nat Rev Neurol. 2016;12(8):455–64. 5. Agostoni EC et al. J Headache Pain. 2019;20(1):92.